Interleukin-11 to Enter Phase III

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinant human interleukin-11 (rhIL-11) restored platelets in throm-bocytopenic patients undergoing cancer chemotherapy to the extent that significantly fewer rhIL-11 treated patients required platelet transfusions, compared to placebo.

CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinanthuman interleukin-11 (rhIL-11) restored platelets in throm-bocytopenicpatients undergoing cancer chemotherapy to the extent that significantlyfewer rhIL-11 treated patients required platelet transfusions,compared to placebo.

Based on this favorable outcome, the company plans to begin aphase III study by the end of this year.

Articles in this issue
ODAC Recommends Accelerated FDA Approval of Ethyol for Cytoprotection
House Panel Holds Hearing on Self-Referral
Health-Related Legislation
Mitoguazone Appears Promising in HIV-Associated Refractory NHL
Responses to Anti-HER2 MoAb Seen
NCI Committed to Increasing Minority Participation in Clinical Trials
MoAb May Improve Detection of Colon And Rectal Cancer
Zeneca Files NDA for Arimidex
Cord Blood is Used as Source of Stem Cells for Pediatric Transplantation
Gemcitabine/Cisplatin Shows Good Response Rate And Favorable Toxicity Profile in Advanced NSCLC
HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and Abuse
M.D. Anderson Holds First Cancer Meeting in Spanish
Molecular Markers Predict Clinical Outcome
NCAB Has Concerns About Future of Clinical Research
IP Interleukin-2 Shows Durable Responses in Ovarian Cancer
Recent Videos
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
6 experts are featured in this series.
Related Content
Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

ONCOLOGY Staff
February 22nd 2025
Article

Hematology oncology experts discuss recent developments in CAR T-cell therapies as well as bispecific therapies for the treatment of patients with R/R MM.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tim Cortese
February 21st 2025
Article

Tambiciclib plus zanubrutinib doubled the expected ORR of zanubrutinib monotherapy, eliciting an ORR of 67% in patients with relapsed or refractory DLBCL.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

Improving End-of-Life Care in ICD Users With Advanced Cancers

Megan Mullins, PhD, MPH
February 20th 2025
Article

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC

Roman Fabbricatore
February 20th 2025
Article

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.